Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation

G. Aicardi, L. Benso, M. Vignolo, A. Terragna, E. Verrina, G. Cordone, R. Coppo, O. Sernia, M. L. Sardella, E. Di Battista, A. Naselli, S. Milani

Research output: Contribution to journalArticle

Abstract

Deflazacort (DFZ), a new glucocorticoid which has recently become available, is expected to have less negative effects on growth and skeletal maturation than conventional steroids. in children treated long term. To verify this hypothesis, a multicentre trial was organized to evaluate the effects of DFZ vs prednisone (PAN) on statural growth and skeletal maturation in a group of prepubertal children requiring glucocorticoid therapy for at least 6 months/year. The results of an analysis of 55 children (aged 3-12 years, 24 with connective tissue disease and 31 with kidney glomerular disorders) treated randomly with either DFZ (31 patients) or PAN (24 patients) and followed for a mean period of about 22 months (16 months under steroid therapy) are presented. The observation period was split up into the following phases according to dose and administration regimen: daily, highdose therapy; alternate-day, high-dose therapy; low-dose therapy; suspension of treatment. The height, statural age, skeletal age and body weight velocities (i.e. the increase/year) were considered. In spite of large intra-individual and inter-individual variability, the results suggest that DFZ has a lower negative impact on indicators of growth. During high-dose daily administration, the height velocity tended to be lower in the PAN group and the impairment of skeletal maturity was significantly less for DFZ than for PDN. During an alternate-day regimen, height velocity was slightly higher in the PAN group and skeletal age velocity was higher in the DFZ group. It seems that steroid effects on statural growth and bone maturation occur in parallel. PAN induced a significantly greater increase in body weight than DFZ. It is worth noting that growth was not suppressed when low doses of DFZ or PAN were administered. During the suspended treatment phase, no prominent catch up growth was observed in either of the two treatment groups, as reflected by the statural indices.

Original languageEnglish
Pages (from-to)39-43
Number of pages5
JournalBritish Journal of Rheumatology
Volume32
Issue numberSUPPL. 2
Publication statusPublished - 1993

Fingerprint

Prednisone
Growth
Steroids
Therapeutics
Glucocorticoids
Body Weight
Connective Tissue Diseases
deflazacort
Bone Development
Multicenter Studies
Suspensions
Age Groups
Observation
Kidney

Keywords

  • Connective tissue disease
  • Deflazacort
  • Glomerular disease
  • Height velocity
  • Prednisone
  • Skeletal maturity
  • Weight velocity

ASJC Scopus subject areas

  • Rheumatology
  • Neuroscience(all)

Cite this

Aicardi, G., Benso, L., Vignolo, M., Terragna, A., Verrina, E., Cordone, G., ... Milani, S. (1993). Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation. British Journal of Rheumatology, 32(SUPPL. 2), 39-43.

Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation. / Aicardi, G.; Benso, L.; Vignolo, M.; Terragna, A.; Verrina, E.; Cordone, G.; Coppo, R.; Sernia, O.; Sardella, M. L.; Di Battista, E.; Naselli, A.; Milani, S.

In: British Journal of Rheumatology, Vol. 32, No. SUPPL. 2, 1993, p. 39-43.

Research output: Contribution to journalArticle

Aicardi, G, Benso, L, Vignolo, M, Terragna, A, Verrina, E, Cordone, G, Coppo, R, Sernia, O, Sardella, ML, Di Battista, E, Naselli, A & Milani, S 1993, 'Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation', British Journal of Rheumatology, vol. 32, no. SUPPL. 2, pp. 39-43.
Aicardi G, Benso L, Vignolo M, Terragna A, Verrina E, Cordone G et al. Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation. British Journal of Rheumatology. 1993;32(SUPPL. 2):39-43.
Aicardi, G. ; Benso, L. ; Vignolo, M. ; Terragna, A. ; Verrina, E. ; Cordone, G. ; Coppo, R. ; Sernia, O. ; Sardella, M. L. ; Di Battista, E. ; Naselli, A. ; Milani, S. / Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation. In: British Journal of Rheumatology. 1993 ; Vol. 32, No. SUPPL. 2. pp. 39-43.
@article{f5dc6921dae946bb921aaa86f7bb13e7,
title = "Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation",
abstract = "Deflazacort (DFZ), a new glucocorticoid which has recently become available, is expected to have less negative effects on growth and skeletal maturation than conventional steroids. in children treated long term. To verify this hypothesis, a multicentre trial was organized to evaluate the effects of DFZ vs prednisone (PAN) on statural growth and skeletal maturation in a group of prepubertal children requiring glucocorticoid therapy for at least 6 months/year. The results of an analysis of 55 children (aged 3-12 years, 24 with connective tissue disease and 31 with kidney glomerular disorders) treated randomly with either DFZ (31 patients) or PAN (24 patients) and followed for a mean period of about 22 months (16 months under steroid therapy) are presented. The observation period was split up into the following phases according to dose and administration regimen: daily, highdose therapy; alternate-day, high-dose therapy; low-dose therapy; suspension of treatment. The height, statural age, skeletal age and body weight velocities (i.e. the increase/year) were considered. In spite of large intra-individual and inter-individual variability, the results suggest that DFZ has a lower negative impact on indicators of growth. During high-dose daily administration, the height velocity tended to be lower in the PAN group and the impairment of skeletal maturity was significantly less for DFZ than for PDN. During an alternate-day regimen, height velocity was slightly higher in the PAN group and skeletal age velocity was higher in the DFZ group. It seems that steroid effects on statural growth and bone maturation occur in parallel. PAN induced a significantly greater increase in body weight than DFZ. It is worth noting that growth was not suppressed when low doses of DFZ or PAN were administered. During the suspended treatment phase, no prominent catch up growth was observed in either of the two treatment groups, as reflected by the statural indices.",
keywords = "Connective tissue disease, Deflazacort, Glomerular disease, Height velocity, Prednisone, Skeletal maturity, Weight velocity",
author = "G. Aicardi and L. Benso and M. Vignolo and A. Terragna and E. Verrina and G. Cordone and R. Coppo and O. Sernia and Sardella, {M. L.} and {Di Battista}, E. and A. Naselli and S. Milani",
year = "1993",
language = "English",
volume = "32",
pages = "39--43",
journal = "British Journal of Rheumatology",
issn = "0263-7103",
publisher = "Oxford University Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation

AU - Aicardi, G.

AU - Benso, L.

AU - Vignolo, M.

AU - Terragna, A.

AU - Verrina, E.

AU - Cordone, G.

AU - Coppo, R.

AU - Sernia, O.

AU - Sardella, M. L.

AU - Di Battista, E.

AU - Naselli, A.

AU - Milani, S.

PY - 1993

Y1 - 1993

N2 - Deflazacort (DFZ), a new glucocorticoid which has recently become available, is expected to have less negative effects on growth and skeletal maturation than conventional steroids. in children treated long term. To verify this hypothesis, a multicentre trial was organized to evaluate the effects of DFZ vs prednisone (PAN) on statural growth and skeletal maturation in a group of prepubertal children requiring glucocorticoid therapy for at least 6 months/year. The results of an analysis of 55 children (aged 3-12 years, 24 with connective tissue disease and 31 with kidney glomerular disorders) treated randomly with either DFZ (31 patients) or PAN (24 patients) and followed for a mean period of about 22 months (16 months under steroid therapy) are presented. The observation period was split up into the following phases according to dose and administration regimen: daily, highdose therapy; alternate-day, high-dose therapy; low-dose therapy; suspension of treatment. The height, statural age, skeletal age and body weight velocities (i.e. the increase/year) were considered. In spite of large intra-individual and inter-individual variability, the results suggest that DFZ has a lower negative impact on indicators of growth. During high-dose daily administration, the height velocity tended to be lower in the PAN group and the impairment of skeletal maturity was significantly less for DFZ than for PDN. During an alternate-day regimen, height velocity was slightly higher in the PAN group and skeletal age velocity was higher in the DFZ group. It seems that steroid effects on statural growth and bone maturation occur in parallel. PAN induced a significantly greater increase in body weight than DFZ. It is worth noting that growth was not suppressed when low doses of DFZ or PAN were administered. During the suspended treatment phase, no prominent catch up growth was observed in either of the two treatment groups, as reflected by the statural indices.

AB - Deflazacort (DFZ), a new glucocorticoid which has recently become available, is expected to have less negative effects on growth and skeletal maturation than conventional steroids. in children treated long term. To verify this hypothesis, a multicentre trial was organized to evaluate the effects of DFZ vs prednisone (PAN) on statural growth and skeletal maturation in a group of prepubertal children requiring glucocorticoid therapy for at least 6 months/year. The results of an analysis of 55 children (aged 3-12 years, 24 with connective tissue disease and 31 with kidney glomerular disorders) treated randomly with either DFZ (31 patients) or PAN (24 patients) and followed for a mean period of about 22 months (16 months under steroid therapy) are presented. The observation period was split up into the following phases according to dose and administration regimen: daily, highdose therapy; alternate-day, high-dose therapy; low-dose therapy; suspension of treatment. The height, statural age, skeletal age and body weight velocities (i.e. the increase/year) were considered. In spite of large intra-individual and inter-individual variability, the results suggest that DFZ has a lower negative impact on indicators of growth. During high-dose daily administration, the height velocity tended to be lower in the PAN group and the impairment of skeletal maturity was significantly less for DFZ than for PDN. During an alternate-day regimen, height velocity was slightly higher in the PAN group and skeletal age velocity was higher in the DFZ group. It seems that steroid effects on statural growth and bone maturation occur in parallel. PAN induced a significantly greater increase in body weight than DFZ. It is worth noting that growth was not suppressed when low doses of DFZ or PAN were administered. During the suspended treatment phase, no prominent catch up growth was observed in either of the two treatment groups, as reflected by the statural indices.

KW - Connective tissue disease

KW - Deflazacort

KW - Glomerular disease

KW - Height velocity

KW - Prednisone

KW - Skeletal maturity

KW - Weight velocity

UR - http://www.scopus.com/inward/record.url?scp=0027276471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027276471&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 39

EP - 43

JO - British Journal of Rheumatology

JF - British Journal of Rheumatology

SN - 0263-7103

IS - SUPPL. 2

ER -